Scalable production and application of Pichia pastoris whole cell catalysts expressing human cytochrome P450 2C9
Abstract Background Currently, the numerous and versatile applications in pharmaceutical and chemical industry make the recombinant production of cytochrome P450 enzymes (CYPs) of great biotechnological interest. Accelerating the drug development process by simple, quick and scalable access of human...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | Microbial Cell Factories |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12934-021-01577-4 |
id |
doaj-1f2f265f88be497a87493bbd47e289ac |
---|---|
record_format |
Article |
spelling |
doaj-1f2f265f88be497a87493bbd47e289ac2021-05-02T11:29:06ZengBMCMicrobial Cell Factories1475-28592021-04-0120111310.1186/s12934-021-01577-4Scalable production and application of Pichia pastoris whole cell catalysts expressing human cytochrome P450 2C9Javier Garrigós-Martínez0Astrid Weninger1José Luis Montesinos-Seguí2Christian Schmid3Francisco Valero4Claudia Rinnofner5Anton Glieder6Xavier Garcia-Ortega7Department of Chemical, Biological and Environmental Engineering, School of Engineering, Universitat Autònoma de BarcelonaInstitute of Molecular Biotechnology, Graz University of TechnologyDepartment of Chemical, Biological and Environmental Engineering, School of Engineering, Universitat Autònoma de BarcelonaInstitute of Molecular Biotechnology, Graz University of TechnologyDepartment of Chemical, Biological and Environmental Engineering, School of Engineering, Universitat Autònoma de BarcelonaBisy GmbHInstitute of Molecular Biotechnology, Graz University of TechnologyDepartment of Chemical, Biological and Environmental Engineering, School of Engineering, Universitat Autònoma de BarcelonaAbstract Background Currently, the numerous and versatile applications in pharmaceutical and chemical industry make the recombinant production of cytochrome P450 enzymes (CYPs) of great biotechnological interest. Accelerating the drug development process by simple, quick and scalable access of human drug metabolites is key for efficient and targeted drug development in response to new and sometimes unexpected medical challenges and needs. However, due its biochemical complexity, scalable human CYP (hCYP) production and their application in preparative biotransformations was still in its infancy. Results A scalable bioprocess for fine-tuned co-expression of hCYP2C9 and its essential complementary human cytochrome P450 reductase (hCPR) in the yeast Pichia pastoris (Komagataella phaffii) is presented. High-throughput screening (HTS) of a transformant library employing a set of diverse bidirectional expression systems with different regulation patterns and a fluorimetric assay was used in order to fine-tune hCYP2C9 and hCPR co-expression, and to identify best expressing clonal variants. The bioprocess development for scalable and reliable whole cell biocatalyst production in bioreactors was carried out based on rational optimization criteria. Among the different alternatives studied, a glycerol carbon-limiting strategy at high µ showed highest production rates, while methanol co-addition together with a decrease of µ provided the best results in terms of product to biomass yield and whole cell activity. By implementing the mentioned strategies, up to threefold increases in terms of production rates and/or yield could be achieved in comparison with initial tests. Finally, the performance of the whole cell catalysts was demonstrated successfully in biotransformation using ibuprofen as substrate, demonstrating the expected high selectivity of the human enzyme catalyst for 3′hydroxyibuprofen. Conclusions For the first time a scalable bioprocess for the production of hCYP2C9 whole cell catalysts was successfully designed and implemented in bioreactor cultures, and as well, further tested in a preparative-scale biotransformation of interest. The catalyst engineering procedure demonstrated the efficiency of the employment of a set of differently regulated bidirectional promoters to identify transformants with most effective membrane-bound hCYP/hCPR co-expression ratios and implies to become a model case for the generation of other P. pastoris based catalysts relying on co-expressed enzymes such as other P450 catalysts or enzymes relying on co-expressed enzymes for co-factor regeneration.https://doi.org/10.1186/s12934-021-01577-4Bidirectional promotersHuman CYP2C9IbuprofenPichia pastorisBioprocess optimisationWhole cell biocatalyst |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Javier Garrigós-Martínez Astrid Weninger José Luis Montesinos-Seguí Christian Schmid Francisco Valero Claudia Rinnofner Anton Glieder Xavier Garcia-Ortega |
spellingShingle |
Javier Garrigós-Martínez Astrid Weninger José Luis Montesinos-Seguí Christian Schmid Francisco Valero Claudia Rinnofner Anton Glieder Xavier Garcia-Ortega Scalable production and application of Pichia pastoris whole cell catalysts expressing human cytochrome P450 2C9 Microbial Cell Factories Bidirectional promoters Human CYP2C9 Ibuprofen Pichia pastoris Bioprocess optimisation Whole cell biocatalyst |
author_facet |
Javier Garrigós-Martínez Astrid Weninger José Luis Montesinos-Seguí Christian Schmid Francisco Valero Claudia Rinnofner Anton Glieder Xavier Garcia-Ortega |
author_sort |
Javier Garrigós-Martínez |
title |
Scalable production and application of Pichia pastoris whole cell catalysts expressing human cytochrome P450 2C9 |
title_short |
Scalable production and application of Pichia pastoris whole cell catalysts expressing human cytochrome P450 2C9 |
title_full |
Scalable production and application of Pichia pastoris whole cell catalysts expressing human cytochrome P450 2C9 |
title_fullStr |
Scalable production and application of Pichia pastoris whole cell catalysts expressing human cytochrome P450 2C9 |
title_full_unstemmed |
Scalable production and application of Pichia pastoris whole cell catalysts expressing human cytochrome P450 2C9 |
title_sort |
scalable production and application of pichia pastoris whole cell catalysts expressing human cytochrome p450 2c9 |
publisher |
BMC |
series |
Microbial Cell Factories |
issn |
1475-2859 |
publishDate |
2021-04-01 |
description |
Abstract Background Currently, the numerous and versatile applications in pharmaceutical and chemical industry make the recombinant production of cytochrome P450 enzymes (CYPs) of great biotechnological interest. Accelerating the drug development process by simple, quick and scalable access of human drug metabolites is key for efficient and targeted drug development in response to new and sometimes unexpected medical challenges and needs. However, due its biochemical complexity, scalable human CYP (hCYP) production and their application in preparative biotransformations was still in its infancy. Results A scalable bioprocess for fine-tuned co-expression of hCYP2C9 and its essential complementary human cytochrome P450 reductase (hCPR) in the yeast Pichia pastoris (Komagataella phaffii) is presented. High-throughput screening (HTS) of a transformant library employing a set of diverse bidirectional expression systems with different regulation patterns and a fluorimetric assay was used in order to fine-tune hCYP2C9 and hCPR co-expression, and to identify best expressing clonal variants. The bioprocess development for scalable and reliable whole cell biocatalyst production in bioreactors was carried out based on rational optimization criteria. Among the different alternatives studied, a glycerol carbon-limiting strategy at high µ showed highest production rates, while methanol co-addition together with a decrease of µ provided the best results in terms of product to biomass yield and whole cell activity. By implementing the mentioned strategies, up to threefold increases in terms of production rates and/or yield could be achieved in comparison with initial tests. Finally, the performance of the whole cell catalysts was demonstrated successfully in biotransformation using ibuprofen as substrate, demonstrating the expected high selectivity of the human enzyme catalyst for 3′hydroxyibuprofen. Conclusions For the first time a scalable bioprocess for the production of hCYP2C9 whole cell catalysts was successfully designed and implemented in bioreactor cultures, and as well, further tested in a preparative-scale biotransformation of interest. The catalyst engineering procedure demonstrated the efficiency of the employment of a set of differently regulated bidirectional promoters to identify transformants with most effective membrane-bound hCYP/hCPR co-expression ratios and implies to become a model case for the generation of other P. pastoris based catalysts relying on co-expressed enzymes such as other P450 catalysts or enzymes relying on co-expressed enzymes for co-factor regeneration. |
topic |
Bidirectional promoters Human CYP2C9 Ibuprofen Pichia pastoris Bioprocess optimisation Whole cell biocatalyst |
url |
https://doi.org/10.1186/s12934-021-01577-4 |
work_keys_str_mv |
AT javiergarrigosmartinez scalableproductionandapplicationofpichiapastoriswholecellcatalystsexpressinghumancytochromep4502c9 AT astridweninger scalableproductionandapplicationofpichiapastoriswholecellcatalystsexpressinghumancytochromep4502c9 AT joseluismontesinossegui scalableproductionandapplicationofpichiapastoriswholecellcatalystsexpressinghumancytochromep4502c9 AT christianschmid scalableproductionandapplicationofpichiapastoriswholecellcatalystsexpressinghumancytochromep4502c9 AT franciscovalero scalableproductionandapplicationofpichiapastoriswholecellcatalystsexpressinghumancytochromep4502c9 AT claudiarinnofner scalableproductionandapplicationofpichiapastoriswholecellcatalystsexpressinghumancytochromep4502c9 AT antonglieder scalableproductionandapplicationofpichiapastoriswholecellcatalystsexpressinghumancytochromep4502c9 AT xaviergarciaortega scalableproductionandapplicationofpichiapastoriswholecellcatalystsexpressinghumancytochromep4502c9 |
_version_ |
1721492157683990528 |